Literature DB >> 23430851

Successful plasmapheresis for acute and severe unconjugated hyperbilirubinemia in a child with crigler najjar type I syndrome.

Anne Laure Sellier1, Philippe Labrune, Theresa Kwon, Alix Mollet Boudjemline, Georges Deschènes, Vincent Gajdos.   

Abstract

Crigler-Najjar syndrome type I (CN-I, MIM #218800) is a rare and severe autosomal disorder. It is caused by deficiency of the liver enzyme responsible for bilirubin elimination, the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1; EC 2.4.1.17). Biologically, the disease manifests itself with severe and persistent unconjugated hyperbilirubinemia. Kernicterus is a well-known complication of severe unconjugated hyperbilirubinemia in infants and young children, especially in patients with CN-I.Few articles have shown the efficiency of plasmapheresis for extreme hyperbilirubinemia.In this report, we describe the efficiency of plasmapheresis for a rapid control of acute and severe unconjugated hyperbilirubinemia in a 6-year-old CN-I patient who had previously developed kernicterus in the neonatal period. In spite of intensification of phototherapy, the patient developed severe hyperbilirubinemia (up to 830 μmol/l, with bilirubin/albumin ratio at 1.2). With two plasmapheresis procedures, bilirubin serum concentration decreased to 420 μmol/ and bilirubin/albumin ratio to 0.55. Following the acute episode of very severe unconjugated hyperbilirubinemia, the child recovered and neurological examination was unchanged, thus suggesting that plasmapheresis possibly prevented further worsening of kernicterus.

Entities:  

Year:  2011        PMID: 23430851      PMCID: PMC3509837          DOI: 10.1007/8904_2011_40

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  13 in total

1.  A method for interdicting the development of severe jaundice in newborns by inhibiting the production of bilirubin.

Authors:  Attallah Kappas
Journal:  Pediatrics       Date:  2004-01       Impact factor: 7.124

2.  Cerebellar symptoms as the presenting manifestations of bilirubin encephalopathy in children with Crigler-Najjar type I disease.

Authors:  P H Labrune; A Myara; J Francoual; F Trivin; M Odièvre
Journal:  Pediatrics       Date:  1992-04       Impact factor: 7.124

3.  Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease.

Authors:  Kevin A Strauss; Donna L Robinson; Hendrik J Vreman; Erik G Puffenberger; Graham Hart; D Holmes Morton
Journal:  Eur J Pediatr       Date:  2006-01-25       Impact factor: 3.183

4.  The Tunisian population history through the Crigler-Najjar type I syndrome.

Authors:  François M Petit; Stéphane Bézieau; Vincent Gajdos; Frédéric Parisot; Catherine Scoul; Liliane Capel; Volodia Stozinic; Naïma Khrouf; Ridha M'Rad; Abraham Koshy; Alix Mollet-Boudjemline; Jeanne Francoual; Philippe Labrune
Journal:  Eur J Hum Genet       Date:  2008-01-16       Impact factor: 4.246

5.  Kernicterus in an adult who is heterozygous for Crigler-Najjar syndrome and homozygous for Gilbert-type genetic defect.

Authors:  N Chalasani; N R Chowdhury; J R Chowdhury; T D Boyer
Journal:  Gastroenterology       Date:  1997-06       Impact factor: 22.682

6.  Crigler-Najjar syndrome: an unusual course with development of neurologic damage at age eighteen.

Authors:  T F Blaschke; P D Berk; B F Scharschmidt; J R Guyther; J M Vergalla; J G Waggoner
Journal:  Pediatr Res       Date:  1974-05       Impact factor: 3.756

Review 7.  Chronic bilirubin encephalopathy: diagnosis and outcome.

Authors:  Steven M Shapiro
Journal:  Semin Fetal Neonatal Med       Date:  2010-01-29       Impact factor: 3.926

Review 8.  Chemoprevention of severe neonatal hyperbilirubinemia.

Authors:  George S Drummond; Attallah Kappas
Journal:  Semin Perinatol       Date:  2004-10       Impact factor: 3.300

9.  Successful plasmapheresis for extreme hyperbilirubinemia caused by acute Epstein-Barr virus.

Authors:  Emily Place; Judith E Wenzel; Ramalingam Arumugam; Kiran Belani; Yoav Messinger
Journal:  J Pediatr Hematol Oncol       Date:  2007-05       Impact factor: 1.289

Review 10.  Pharmacological and clinical aspects of heme oxygenase.

Authors:  Nader G Abraham; Attallah Kappas
Journal:  Pharmacol Rev       Date:  2008-03-06       Impact factor: 25.468

View more
  2 in total

Review 1.  Germline genetic variants with implications for disease risk and therapeutic outcomes.

Authors:  Amy L Pasternak; Kristen M Ward; Jasmine A Luzum; Vicki L Ellingrod; Daniel L Hertz
Journal:  Physiol Genomics       Date:  2017-09-08       Impact factor: 3.107

2.  A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome.

Authors:  Giuseppe Ronzitti; Giulia Bortolussi; Remco van Dijk; Fanny Collaud; Severine Charles; Christian Leborgne; Patrice Vidal; Samia Martin; Bernard Gjata; Marcelo Simon Sola; Laetitia van Wittenberghe; Alban Vignaud; Philippe Veron; Piter J Bosma; Andres F Muro; Federico Mingozzi
Journal:  Mol Ther Methods Clin Dev       Date:  2016-07-20       Impact factor: 6.698

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.